Zydus receives USFDA approval for Ranolazine Extended-Release Tablets

Zydus Cadila has received the final approval from the USFDA to market Ranolazine Extended- Release Tablets (US RLD Ranexa®), 500 mg and 1.000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control. It will be manufactured at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News